Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial
M Davies, B Bode, R Kushner, A Lewin, T Vang Skjøth, CB Jensen, R De Fronzo, J Kienhöfer, A Pfeiffer · Diabetologie und Stoffwechsel · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Liraglutide at doses up to 1.8 mg in combination with OADs and/or basal insulin is approved for the treatment of T2D. The randomized, double-blind, placebo-controlled trial SCALE Diabetes (NCT01272232) investigated the efficacy and safety of liraglutide 3.0 mg, as adjunct to diet and exercise, for weight management in obese/overweight adults with T2D. 846 individuals (age 54.9 years, M/F 50:50, BMI 37.1 kg/m2 [27.0 – 67.6], HbA1c 7.9%, FPG 8.8 (1.9 SD) mmol/L [4.2 – 17.3], T2D duration 7.3 years [0.2 – 36.5], 11.5% on diet and exercise, 57.3% on metformin, and 31.2% combination therapy or SU monotherapy) were ra…
